Renal denervation trials in hypertension – what we wait for in 2023/2024
- 18 September 2023
- journal article
- editorial
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 117, 55-56
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Phase 2 Trial of Baxdrostat for Treatment-Resistant HypertensionNew England Journal of Medicine, 2023
- Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure RangeJACC, 2022
- Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialThe Lancet, 2021
- Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trialThe Lancet, 2020
- Device-based therapies for arterial hypertensionNature Reviews Cardiology, 2020
- Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2018
- Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialThe Lancet, 2018
- Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trialThe Lancet, 2018
- Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialThe Lancet, 2017
- Global Disparities of Hypertension Prevalence and ControlCirculation, 2016